Report: 700 follow-on biologics therapies currently moving through pipelines worldwide
- Big pharma and generics makers face a steep learning curve. While generic makers currently lead the pack, the expertise in this market is held by the biologics makers. New pure-play biosimilar makers funded by governments and private investors also have a strong presence in this arena;
- Biosimilars promise to deliver big savings. Typically offering 20% to 30% discounts from innovator biologics, biosimilars are expected to deliver $11 billion to $33 billion in savings across the European Union by 2020;
- Start-ups working to make and sell biosimilars in emerging territories could be the "David" ticket to beat pharma "Goliaths" that dominate those realms;
- Slow market uptake of biosimilars in the European Union may not also hold true for the United States. Unlike most of the European Union, the United States will allow interchangeability, which is expected to speed adoption and lead to lower prices;
- The World Health Organization recently proposed a voluntary, global naming scheme that could level the playing field for biosimilars and their reference biologics; and
- In many parts of the world, follow-ons offer new hope to patients who previously did not have access to pricey biologics, bringing the power of biologics for the first time to markets in Africa, Asia, Eastern Europe and Latin America.
L’Oréal, Puma sign licensing deal
CLICHY, France and HERZOGENAURACH, Germany — Beauty brand L’Oréal has inked a licensing deal with sports company Puma for beauty products.
The deal is effective Jan. 1, 2015. Puma’s license contract with Procter & Gamble will terminate on Dec. 31.